Free Newsletter
Emergent buys Protein Sciences in $75M deal
Emergent BioSolutions has inked a deal to buy 25-year-old Protein Sciences for $75 million or more. Protein Sciences has been developing a new flu vaccine, FluBlok, relying on a new method that grows a virus in cells from caterpillars--one of a number of new cellular programs that are aiming at replacing the egg-based approach employed now. Emergent sells an anthrax vaccine and is looking to build a manufacturing facility for the flu vaccine.
"Meriden (Connecticut) is under active consideration for expanded manufacturing as we work to build on the infrastructure that is now in place," Tracey Schmitt, an Emergent spokeswoman, told the Hartford Courant. "We expect to launch FluBlok and to expand production capacity from the Meriden site and to retain all of the approximately 50 employees currently at that location."
- check out Emergent's release
- read the report in the Hartford Courant
- read the story in the Washington Post
Related Articles:
Emergent BioSolutions buys flu vaccine maker
Emergent BioSolutions files $86M IPO
Struggling VaxGen sells anthrax vaccine to rival
More stories about undefined
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: